- Home
- IROQ vs ABOS Comparison
IROQ vs ABOS Comparison
Compare IROQ & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IROQ
- ABOS
- Stock Information
- Founded
- IROQ 1883
- ABOS 1996
- Country
- IROQ United States
- ABOS United States
- Employees
- IROQ N/A
- ABOS N/A
- Industry
- IROQ Savings Institutions
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- IROQ Finance
- ABOS Health Care
- Exchange
- IROQ Nasdaq
- ABOS Nasdaq
- Market Cap
- IROQ 75.8M
- ABOS 66.6M
- IPO Year
- IROQ 2011
- ABOS 2021
- Fundamental
- Price
- IROQ $23.96
- ABOS $0.98
- Analyst Decision
- IROQ
- ABOS Strong Buy
- Analyst Count
- IROQ 0
- ABOS 3
- Target Price
- IROQ N/A
- ABOS $7.33
- AVG Volume (30 Days)
- IROQ 1.1K
- ABOS 211.3K
- Earning Date
- IROQ 04-29-2025
- ABOS 05-13-2025
- Dividend Yield
- IROQ 1.66%
- ABOS N/A
- EPS Growth
- IROQ 69.23
- ABOS N/A
- EPS
- IROQ 1.05
- ABOS N/A
- Revenue
- IROQ $25,099,000.00
- ABOS N/A
- Revenue This Year
- IROQ N/A
- ABOS N/A
- Revenue Next Year
- IROQ N/A
- ABOS N/A
- P/E Ratio
- IROQ $23.01
- ABOS N/A
- Revenue Growth
- IROQ 12.02
- ABOS N/A
- 52 Week Low
- IROQ $14.85
- ABOS $0.86
- 52 Week High
- IROQ $25.76
- ABOS $3.92
- Technical
- Relative Strength Index (RSI)
- IROQ 50.35
- ABOS 42.74
- Support Level
- IROQ $23.80
- ABOS $0.96
- Resistance Level
- IROQ $24.46
- ABOS $1.13
- Average True Range (ATR)
- IROQ 0.18
- ABOS 0.09
- MACD
- IROQ 0.03
- ABOS 0.00
- Stochastic Oscillator
- IROQ 58.78
- ABOS 14.26
About IROQ IF Bancorp Inc.
IF Bancorp Inc is a holding company. It is mainly engaged in the business of directing, planning, and coordinating the business activities of Iroquois Federal. The company with the association take deposits from the general public and invest those deposits together with funds generated from operations and borrowings in various loans such as multi-family residential and mortgage loans, commercial real estate loans, home equity lines of credit, consumer loans, others and also a variety of deposit accounts and alternative delivery channels.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.